Iridex (IRIX) Capital Expenditures Growth (1y) (2012 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 27.22% |
| 10 | Iridex | 18.87 Mn | 14.27 Mn | 4.74 Mn | 818.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 4, 2026 | 818.18% |
| Jan 3, 2026 | 1,077.78% |
| Sep 27, 2025 | 1,200.00% |
| Mar 29, 2025 | 266.67% |
| Dec 28, 2024 | 128.13% |
| Sep 28, 2024 | -98.78% |
| Mar 30, 2024 | -93.02% |
| Dec 30, 2023 | -138.55% |
| Sep 30, 2023 | 43.86% |
| Jul 1, 2023 | -86.67% |
| Apr 1, 2023 | 65.38% |
| Dec 31, 2022 | -34.13% |
| Apr 2, 2022 | -64.38% |
| Apr 3, 2021 | 7.35% |
| Sep 26, 2020 | -42.86% |
| Jun 27, 2020 | -75.00% |
| Mar 28, 2020 | 1.49% |
| Dec 28, 2019 | -93.88% |
| Sep 28, 2019 | -17.65% |
| Jun 29, 2019 | -56.00% |
| Mar 30, 2019 | -75.55% |
| Dec 29, 2018 | 48.48% |
| Sep 29, 2018 | -83.96% |
| Jun 30, 2018 | 5.26% |
| Mar 31, 2018 | -19.65% |
| Dec 30, 2017 | -87.78% |
| Sep 30, 2017 | -75.06% |
| Jul 1, 2017 | -65.83% |
| Apr 1, 2017 | 283.15% |
| Dec 31, 2016 | -33.00% |
| Apr 2, 2016 | -77.58% |
| Apr 4, 2015 | 267.59% |
| Sep 27, 2014 | -21.47% |
| Jun 28, 2014 | 337.04% |
| Mar 29, 2014 | 500.00% |
| Dec 28, 2013 | 72.62% |
| Sep 28, 2013 | 19.85% |
| Jun 29, 2013 | 1.89% |
| Mar 30, 2013 | -85.12% |
| Dec 29, 2012 | 33.33% |
| Sep 29, 2012 | 30.77% |
| Mar 31, 2012 | 236.11% |